FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
ARCA biopharma, Inc. Stock AnalysisComprehensive stock analysis for ARCA biopharma, Inc. (ABIO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisABIO
ABIO
ARCA biopharma, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ABIO
Home🔹Stocks🔹ARCA biopharma, Inc.

ARCA biopharma, Inc.

ABIO•NASDAQ

ARCA biopharma, Inc.

ABIO•NASDAQ
Market cap
$34.82M
Sentiment

Your view on ABIO

Mkt Cap
$34.82M
Sentiment
Your view
ABIO
ARCA biopharma, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ABIO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ARCA biopharma, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Thomas A. Keuer
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Thomas A. Keuer
Headquarters
US
Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News